Menu Search
Equities

Appili Therapeutics Inc

APLIF:PKC

Appili Therapeutics Inc

Actions
  • Price (USD)0.023
  • Today's Change-0.002 / -9.65%
  • Shares traded255.00k
  • 1 Year change-18.04%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 18:33 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701 and ATI-1801. LIKMEZ (ATI-1501) is its advanced commercial stage asset, a liquid oral reformulation of the antibiotic metronidazole to treat serious anaerobic and protozoal infections. ATI-1701 is a live-attenuated vaccine for Francisella tularensis (F. tularensis), the bacterium which causes tularemia. ATI-1801 is a topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis.

  • Revenue in CAD (TTM)827.41k
  • Net income in CAD-3.82m
  • Incorporated2015
  • Employees7.00
  • Location
    Appili Therapeutics Inc#21-1344 Summer StreetHALIFAX B3H 0A8CanadaCAN
  • Phone+1 (902) 442-4655
  • Fax+1 (902) 442-4655
  • Websitehttps://appilitherapeutics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.